Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBrigham and Women's Hospital
About this trial
A single arm, pilot study among individuals with rosacea and at least moderate flushing or rednesss will be enrolled in a 4-week trial of taVNS. The particicpants will be followed for an additional 4-weeks following the intervention period to evaluate the durability of the results
Eligibility criteria
Qualifiers
Adults aged 18 years of age and older
Dermatologist confirmed diagnosis of rosacea
Clinician's Erythema Assessment of at least 3 (moderate to severe disease)
Willingness to adhere to current rosacea regimen without additions or laser treatments (e.g. PDL) during the study period.
Disqualifiers
Changes to rosacea regimen (prescription topical or oral medications) within 4 weeks of randomization.
Facial hair, tattoos, or other characteristics that would interfere with erythema assessments
History of symptomatic cardiac arrythmias (e.g. heart block, sick sinus syndrome, bradyarrhythmia)
Presence of a pacemaker, implanted defibrillator, or neurostimulator
Trial design
Treatments tested in this trial
- Transaricular vagus nerve stimulation (taVNS)
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov